



## Living Cell Technologies Limited

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQX:** LVCLY

### ASX ANNOUNCEMENT

## Preliminary Final Report 30 June 2020

---

**31 August 2020 – Sydney, Australia & Auckland, New Zealand** – Living Cell Technologies Limited (LCT) today announced the Preliminary Final Report (Appendix 4E) on the financial results for the year ended 30 June 2020. In accordance with Listing Rule 4.3A, the report is attached.

The COVID-19 pandemic affected progress in the company's ongoing projects as well as opportunities to progress licensing and partnership discussions, particularly during the second half of the year. This is reflected in the financial results. In the first half of the year the company completed follow up of NTCELL safety and efficacy in our clinical studies of NTCELL in Parkinson's disease and the close out of the Phase I/II and Phase IIb research projects. LCT also made progress in the research partnerships with the University of Auckland that target migraine and obesity.

### Financial Results

The loss after income tax from continuing operations has reduced from a loss of \$(3,181,363) in the year ended 30 June 2019 to a loss of \$(968,469) helped mainly by a profit of \$1,100,159 from the sale of shares in Semma Therapeutics.

Revenue and other income decreased from \$769,677 to \$553,692 due mainly to lower grant income as R & D expenditure reduced in the second half due to COVID-19 restrictions and the closing of the Phase I/II and Phase IIb research projects. Research and development expenses decreased from \$(3,328,905) to \$(2,383,801) due to COVID-19 restrictions and the renegotiation of the migraine and obesity projects with the University of Auckland.

Cash and cash equivalents decreased from \$4,907,957 to \$2,964,874 due to investing into product opportunities while containing costs.

– Ends –

Authorised for release by the Board of Directors.

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<b>At the company:</b> Ken Taylor Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 796000 <a href="mailto:ktaylor@lctglobal.com">ktaylor@lctglobal.com</a>	<b>Media enquires:</b> Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a>
---	--

## **About Living Cell Technologies**

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

As well as NTCELL, LCT is also advancing research collaborations with the University of Auckland to identify products that are candidates for out licensing to global pharmaceutical companies. Projects that have been initiated target obesity and migraine where the lead product candidates utilise patented novel peptide synthetic chemistry technology.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information, visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter.

## **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.